In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.

The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.

It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick succession by the US Food and Drug Administration, then later in 2024, long-awaited ...

For general cardiology and prevention, the year 2024 was all about novel treatments for new targets—be those lipoprotein(a), glucagon-like peptide-1 (GLP-1), or angiotensinogen. But at the same time, ...

Be it bullying, offensive language, or misuse of power, the cardiovascular community took a stand against disruptive behaviors this year, with some cardiovascular societies proactively issuing ...

Medicine is a balancing act, a mosaic of competing priorities. Just this week, I wrapped up a challenging coronary intervention and hurriedly planned a TAVR case before racing against the clock to ...